Titre : Carbonic anhydrase-IV

Carbonic anhydrase-IV : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Carbonic anhydrase-IV : Questions médicales les plus fréquentes", "headline": "Carbonic anhydrase-IV : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Carbonic anhydrase-IV : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-15", "dateModified": "2025-04-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Carbonic anhydrase-IV" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines liées au GPI", "url": "https://questionsmedicales.fr/mesh/D058851", "about": { "@type": "MedicalCondition", "name": "Protéines liées au GPI", "code": { "@type": "MedicalCode", "code": "D058851", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.418" } } }, "about": { "@type": "MedicalCondition", "name": "Carbonic anhydrase-IV", "alternateName": "Carbonic Anhydrase IV", "code": { "@type": "MedicalCode", "code": "D030741", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Claudiu T Supuran", "url": "https://questionsmedicales.fr/author/Claudiu%20T%20Supuran", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy." } }, { "@type": "Person", "name": "Andrea Angeli", "url": "https://questionsmedicales.fr/author/Andrea%20Angeli", "affiliation": { "@type": "Organization", "name": "Department of Neurosciences, Psychology, Drug Research and Child Health, Pharmaceutical and Nutraceutical Section, University of Florence, Sesto Fiorentino, Italy." } }, { "@type": "Person", "name": "Alessio Nocentini", "url": "https://questionsmedicales.fr/author/Alessio%20Nocentini", "affiliation": { "@type": "Organization", "name": "Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Via Ugo Schiff 6, 50019 Florence, Italy." } }, { "@type": "Person", "name": "Clemente Capasso", "url": "https://questionsmedicales.fr/author/Clemente%20Capasso", "affiliation": { "@type": "Organization", "name": "Istituto di Bioscienze e Biorisorse - Consiglio Nazionale delle Ricerche CNR, Via P: Castellino 111, 80131, Naples, Italy." } }, { "@type": "Person", "name": "Marta Ferraroni", "url": "https://questionsmedicales.fr/author/Marta%20Ferraroni", "affiliation": { "@type": "Organization", "name": "University of Florence, Department of Chemistry, via della Lastruccia, 50019 Sesto Fiorentino, Italy." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy.", "datePublished": "2022-10-31", "url": "https://questionsmedicales.fr/article/36479600", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4048/jbc.2022.25.e44" } }, { "@type": "ScholarlyArticle", "name": "Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36153587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12957-022-02766-0" } }, { "@type": "ScholarlyArticle", "name": "Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36098904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24692" } }, { "@type": "ScholarlyArticle", "name": "Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2022.08.020" } }, { "@type": "ScholarlyArticle", "name": "Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35856081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s43856-022-00155-y" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Glycoprotéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008562" }, { "@type": "ListItem", "position": 6, "name": "Protéines liées au GPI", "item": "https://questionsmedicales.fr/mesh/D058851" }, { "@type": "ListItem", "position": 7, "name": "Carbonic anhydrase-IV", "item": "https://questionsmedicales.fr/mesh/D030741" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Carbonic anhydrase-IV - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Carbonic anhydrase-IV", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Carbonic anhydrase-IV", "description": "Comment diagnostiquer une déficience en anhydrase carbonique IV ?\nQuels examens sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec l'enzyme ?\nY a-t-il des marqueurs biologiques spécifiques ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Carbonic anhydrase-IV", "description": "Quels sont les symptômes d'une déficience en anhydrase carbonique IV ?\nComment se manifestent les troubles respiratoires ?\nY a-t-il des symptômes neurologiques associés ?\nLes calculs rénaux sont-ils un symptôme courant ?\nPeut-on observer des symptômes digestifs ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Carbonic anhydrase-IV", "description": "Peut-on prévenir la déficience en anhydrase carbonique IV ?\nY a-t-il des mesures préventives pour les calculs rénaux ?\nLes tests génétiques peuvent-ils aider à la prévention ?\nDes conseils diététiques peuvent-ils prévenir les symptômes ?\nLes activités physiques sont-elles bénéfiques ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Carbonic anhydrase-IV", "description": "Quels traitements sont disponibles pour la déficience ?\nLa thérapie génique est-elle une option ?\nComment gérer les symptômes respiratoires ?\nY a-t-il des médicaments spécifiques à éviter ?\nLes changements alimentaires sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Carbonic anhydrase-IV", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLes troubles respiratoires peuvent-ils s'aggraver ?\nY a-t-il un risque accru de déshydratation ?\nLes complications neurologiques sont-elles possibles ?\nComment les complications sont-elles gérées ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Carbonic anhydrase-IV", "description": "Quels sont les facteurs de risque pour cette déficience ?\nL'âge joue-t-il un rôle dans le risque ?\nLes maladies rénales augmentent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes habitudes alimentaires peuvent-elles affecter le risque ?", "url": "https://questionsmedicales.fr/mesh/D030741?mesh_terms=Early+Detection+of+Cancer&page=998#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en anhydrase carbonique IV ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses sanguines peuvent confirmer la déficience." } }, { "@type": "Question", "name": "Quels examens sont utilisés pour évaluer l'activité de l'enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques dans des échantillons de sang ou de tissus sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec l'enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la déshydratation, des troubles respiratoires ou des calculs rénaux peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques spécifiques ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de bicarbonate dans le sang peuvent indiquer un dysfonctionnement." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les complications, mais n'est pas spécifique au diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en anhydrase carbonique IV ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, déshydratation, et troubles respiratoires." } }, { "@type": "Question", "name": "Comment se manifestent les troubles respiratoires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent se manifester par une respiration rapide ou des difficultés à respirer." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des maux de tête et des troubles de la concentration peuvent survenir." } }, { "@type": "Question", "name": "Les calculs rénaux sont-ils un symptôme courant ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la formation de calculs rénaux est fréquente en cas de déficience." } }, { "@type": "Question", "name": "Peut-on observer des symptômes digestifs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des nausées et des vomissements peuvent également être présents." } }, { "@type": "Question", "name": "Peut-on prévenir la déficience en anhydrase carbonique IV ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives pour les calculs rénaux ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Boire beaucoup d'eau et réduire l'apport en sel peut aider à prévenir les calculs." } }, { "@type": "Question", "name": "Les tests génétiques peuvent-ils aider à la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les personnes à risque." } }, { "@type": "Question", "name": "Des conseils diététiques peuvent-ils prévenir les symptômes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut réduire les symptômes associés." } }, { "@type": "Question", "name": "Les activités physiques sont-elles bénéfiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une activité physique modérée peut améliorer la santé générale et le bien-être." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la déficience ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des suppléments de bicarbonate et une hydratation adéquate." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore disponible pour cette condition." } }, { "@type": "Question", "name": "Comment gérer les symptômes respiratoires ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des bronchodilatateurs peuvent être prescrits pour améliorer la respiration." } }, { "@type": "Question", "name": "Y a-t-il des médicaments spécifiques à éviter ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certains diurétiques peuvent aggraver les symptômes et doivent être évités." } }, { "@type": "Question", "name": "Les changements alimentaires sont-ils recommandés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en liquides et faible en sodium est souvent conseillée." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme l'acidose métabolique et des troubles rénaux peuvent se produire." } }, { "@type": "Question", "name": "Les troubles respiratoires peuvent-ils s'aggraver ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, sans traitement, les troubles respiratoires peuvent devenir graves." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de déshydratation ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent être plus susceptibles de souffrir de déshydratation." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles possibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications neurologiques comme des convulsions peuvent survenir." } }, { "@type": "Question", "name": "Comment les complications sont-elles gérées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion des complications nécessite un suivi médical régulier et des traitements adaptés." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux et certaines mutations génétiques augmentent le risque." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines formes de déficience peuvent se manifester dès l'enfance." } }, { "@type": "Question", "name": "Les maladies rénales augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies rénales préexistantes peuvent exacerber les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines expositions environnementales peuvent influencer le risque de déficience." } }, { "@type": "Question", "name": "Les habitudes alimentaires peuvent-elles affecter le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut contribuer à des complications." } } ] } ] }

Sources (10000 au total)

Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decre... The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21... A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the nu... The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were...

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.

The sensitivity and specificity of current biomarkers for gastric cancer were insufficient. The aim of the present study was to screen novel biomarkers and determine the diagnostic values of ornithine... With stable isotope tags, we labelled an initial discovery group of four paired gastric cancer tissue samples and identified with LC-ESI-MS/MS. A validation group of 159 gastric cancer samples and 30 ... Four hundred and thirty one proteins were found differentially expressed in gastric cancer tissues. Of these proteins, OAT and CPS1 were found over-expressed in gastric cancer patients, with sensitivi... The present findings indicated a tight correlation between the co-expression of OAT and CPS1 and the histological grade, local invasion, and TNM stages of gastric cancer. Therefore, OAT and CPS1 might...

Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.

Among women with early-stage endometrial cancer (EC), age, stage, grade, and histology are used to determine fitness for adjuvant radiation therapy (RT) administration. We examined non-cancer factors ... Using data from the Surveillance Epidemiology and End Results cancer registry program linked with Medicare claims, we identified 25,654 women (aged ≥66 years) diagnosed with first primary stage I-II E... Adjuvant RT was less commonly administered to Asian American and Pacific Islander patients than non-Hispanic White patients (Prevalence ratio [PR], 0.84; 95% confidence interval [CI], 0.73 to 0.97). C... Findings suggest that various non-cancer factors affect the delivery of adjuvant RT to older women with early-stage EC in real-world oncology practice. Advancing our understanding of factors associate...

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.

Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progr... MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized, controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled were assigned to a control arm (... The experimental arm showed no efficacy signal, yet a well-tolerated safety profile in the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were comparable to those in the MORP... Hybrid control provides comparable treatment-effect estimates with generally improved precision, and thus can be of value to inform early-phase clinical development in metastatic colorectal cancer....

Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.

Early biochemical recurrence (eBCR) indicated a high risk for potential recurrence and metastasis in prostate cancer. The N6-methyladenosine (m6A) methylation modification played an important role in ... Pearson correlation analysis was first conducted to explore m6A lncRNAs and univariate Cox regression analysis was further performed to identify m6A lncRNAs of prognostic roles for predicting eBCR in ... Five hundred and thirty-eighth m6A lncRNAs were searched out through Pearson correlation analysis and 25 out of 538 m6A lncRNAs were identified to pose prediction roles for eBCR in prostate cancers. A... The m6A lncRNA signature in this study could be utilized to efficiently predict eBCR occurrence, various clinical characteristic and immune microenvironment for prostate cancer....

MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study.

To investigate whether breast edema characteristics at preoperative T2-weighted imaging (T2WI) could help evaluate axillary lymph node (ALN) burden in patients with early-stage breast cancer.... This retrospective study included women with clinical T1 and T2 stage breast cancer and preoperative MRI examination in two independent cohorts from May 2014 to December 2020. Low (< 3 LNs+) and high ... A total of 1092 patients were included in this study. BES was identified as the independent predictor of pALN burden in primary (n = 677) and validation (n = 415) cohorts. The analysis using MRI-ALN s... In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning.... • In this retrospective study of 1092 patients with early-stage breast cancer from two cohorts, the MRI characteristic of breast edema has independent and additive predictive value for assessing axill...

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer.... Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus... The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),... In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...